Pub Date : 2025-12-24DOI: 10.1053/j.ajkd.2025.11.005
Sumit Mohan,Kundan Jana,Miko E Yu
{"title":"Expanding Our Understanding of Genetic Variations That Impact Post-Transplant Outcomes.","authors":"Sumit Mohan,Kundan Jana,Miko E Yu","doi":"10.1053/j.ajkd.2025.11.005","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.11.005","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"1 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1053/j.ajkd.2025.11.004
Michelle M Estrella
{"title":"Sex Hormones and Effects on Kidney Health: Piecing Together the Science.","authors":"Michelle M Estrella","doi":"10.1053/j.ajkd.2025.11.004","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.11.004","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"10 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145830320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1053/j.ajkd.2025.10.014
Susan F Massengill,Kenneth A Andreoni,Keith A Bellovich,Cheryl Courtlandt,Vimal K Derebail,David L Feldman,Gia J Oh,John W Sleasman,Kristina A Bryant,
People with chronic kidney disease (CKD) are particularly vulnerable to vaccine-preventable infections. Therefore, the National Kidney Foundation organized a multidisciplinary Working Group, including people with CKD and family care partners, to develop recommendations to improve vaccination rates, vaccination effectiveness, and healthcare for the CKD population. A modified Delphi process was used to achieve consensus on the recommendations. Recommendations on vaccination in CKD patients were organized into these categories: 1) Patient preferences; 2) Assessing the Vaccination Status of Patients with CKD; 3) Assessing Vaccine Response in Patients with CKD; 4) Vaccination of Immunocompromised Patients; 5) Vaccination in Post-transplant Patients; 6) Vaccinations in Patients with CKD Before International Travel; 7) Vaccination of Household Contacts of Patients with CKD; 8) Assessing Vaccine Efficacy and Safety in Clinical Trials with Patients with CKD; 9) Training and Resources for Healthcare Teams; 10) Training of Healthcare Teams for Discussions with Patients; 11) Role of Technology in Promoting and Improving Vaccination; and 12) Advocacy and Policy Considerations for Promoting and Improving Vaccination Rates. The working group's recommendations should improve communication between patients and healthcare clinicians, inclusion of people with CKD in vaccine trials, use of existing clinical guidelines, generating educational resources and training materials for CKD patients of all ages and healthcare professionals.
{"title":"Improving Vaccination in People With CKD: Report From a National Kidney Foundation Working Group.","authors":"Susan F Massengill,Kenneth A Andreoni,Keith A Bellovich,Cheryl Courtlandt,Vimal K Derebail,David L Feldman,Gia J Oh,John W Sleasman,Kristina A Bryant, ","doi":"10.1053/j.ajkd.2025.10.014","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.10.014","url":null,"abstract":"People with chronic kidney disease (CKD) are particularly vulnerable to vaccine-preventable infections. Therefore, the National Kidney Foundation organized a multidisciplinary Working Group, including people with CKD and family care partners, to develop recommendations to improve vaccination rates, vaccination effectiveness, and healthcare for the CKD population. A modified Delphi process was used to achieve consensus on the recommendations. Recommendations on vaccination in CKD patients were organized into these categories: 1) Patient preferences; 2) Assessing the Vaccination Status of Patients with CKD; 3) Assessing Vaccine Response in Patients with CKD; 4) Vaccination of Immunocompromised Patients; 5) Vaccination in Post-transplant Patients; 6) Vaccinations in Patients with CKD Before International Travel; 7) Vaccination of Household Contacts of Patients with CKD; 8) Assessing Vaccine Efficacy and Safety in Clinical Trials with Patients with CKD; 9) Training and Resources for Healthcare Teams; 10) Training of Healthcare Teams for Discussions with Patients; 11) Role of Technology in Promoting and Improving Vaccination; and 12) Advocacy and Policy Considerations for Promoting and Improving Vaccination Rates. The working group's recommendations should improve communication between patients and healthcare clinicians, inclusion of people with CKD in vaccine trials, use of existing clinical guidelines, generating educational resources and training materials for CKD patients of all ages and healthcare professionals.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"10 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145823890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1053/j.ajkd.2025.09.024
Joanna Q Hudson,Alex R Chang,Amanda J Condon Martinez,Rebecca Maxson,Calvin J Meaney,Wendy L St Peter
Comprehensive medication management (CMM) is the standard of care that ensures medications are individually assessed to determine that each medication is appropriate, effective for the medical condition, safe given the patient's comorbidities and other medications, and able to be taken by the patient as intended. CMM helps improve all aspects of healthcare quality and is essential for individuals with chronic kidney disease (CKD). It specifically addresses the complexity of medication regimens in patients with multiple comorbid conditions that often lead to medication therapy problems. Provision of CMM is best optimized with a multidisciplinary team that includes a pharmacist. The importance of interprofessional and multidisciplinary practice in the care of individuals with kidney disease has been emphasized by nephrology organizations and within CKD related guidelines. The shift towards pay for performance and value-based care models within nephrology has created more opportunities for pharmacist integration into care teams. Other health care providers should view the inclusion of pharmacists in the kidney care team as a valuable opportunity to enhance patient support, reduce work-related stress and improve outcomes through collaborative teamwork. The Advancing Kidney Health through Optimal Medication Management initiative supports the involvement of pharmacists across practices and healthcare systems to ensure successful implementation of CMM for individuals with kidney disease.
{"title":"Optimizing Comprehensive Medication Management in CKD: An Opportunity to Integrate Pharmacists in the Kidney Care Team.","authors":"Joanna Q Hudson,Alex R Chang,Amanda J Condon Martinez,Rebecca Maxson,Calvin J Meaney,Wendy L St Peter","doi":"10.1053/j.ajkd.2025.09.024","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.09.024","url":null,"abstract":"Comprehensive medication management (CMM) is the standard of care that ensures medications are individually assessed to determine that each medication is appropriate, effective for the medical condition, safe given the patient's comorbidities and other medications, and able to be taken by the patient as intended. CMM helps improve all aspects of healthcare quality and is essential for individuals with chronic kidney disease (CKD). It specifically addresses the complexity of medication regimens in patients with multiple comorbid conditions that often lead to medication therapy problems. Provision of CMM is best optimized with a multidisciplinary team that includes a pharmacist. The importance of interprofessional and multidisciplinary practice in the care of individuals with kidney disease has been emphasized by nephrology organizations and within CKD related guidelines. The shift towards pay for performance and value-based care models within nephrology has created more opportunities for pharmacist integration into care teams. Other health care providers should view the inclusion of pharmacists in the kidney care team as a valuable opportunity to enhance patient support, reduce work-related stress and improve outcomes through collaborative teamwork. The Advancing Kidney Health through Optimal Medication Management initiative supports the involvement of pharmacists across practices and healthcare systems to ensure successful implementation of CMM for individuals with kidney disease.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"22 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145823888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-20DOI: 10.1053/j.ajkd.2025.10.013
Howard Trachtman,Sean Eddy,Matthias Kretzler
Focal segmental glomerulosclerosis (FSGS) is not a single disease. Instead, it is a histopathological entity that is the manifestation of a wide range of clinical insults that injure the podocyte, a key structural element in the glomerular filtration barrier. The current classification of FSGS includes four subtypes - primary immune-mediated, genetic, secondary, and undetermined cause. Based on this scheme, patients are treated empirically with a combination of non-specific renoprotective drugs and immunosuppressive agents in an effort to reduce proteinuria and preserve kidney function. However, there are no FDA-approved medications for FSGS. Moreover, current therapy is successful in achieving disease remission in less than a quarter of patients and all of the available options are associated with significant side effects that limit their use in practice. Ongoing research using a full array of muti-omics analytical tools including genomic, transcriptomic, proteomic and metabolomic assessment suggest that patients with FSGS can be characterized mechanistically by the primary process(es) initiating and promoting disease progression. This work is summarized in this review and raises the potential to individualize therapy for each patient with FSGS. This would usher in the potential for precision medicine to be applied in the treatment of those affected by this rare but serious glomerular disease.
{"title":"Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review.","authors":"Howard Trachtman,Sean Eddy,Matthias Kretzler","doi":"10.1053/j.ajkd.2025.10.013","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.10.013","url":null,"abstract":"Focal segmental glomerulosclerosis (FSGS) is not a single disease. Instead, it is a histopathological entity that is the manifestation of a wide range of clinical insults that injure the podocyte, a key structural element in the glomerular filtration barrier. The current classification of FSGS includes four subtypes - primary immune-mediated, genetic, secondary, and undetermined cause. Based on this scheme, patients are treated empirically with a combination of non-specific renoprotective drugs and immunosuppressive agents in an effort to reduce proteinuria and preserve kidney function. However, there are no FDA-approved medications for FSGS. Moreover, current therapy is successful in achieving disease remission in less than a quarter of patients and all of the available options are associated with significant side effects that limit their use in practice. Ongoing research using a full array of muti-omics analytical tools including genomic, transcriptomic, proteomic and metabolomic assessment suggest that patients with FSGS can be characterized mechanistically by the primary process(es) initiating and promoting disease progression. This work is summarized in this review and raises the potential to individualize therapy for each patient with FSGS. This would usher in the potential for precision medicine to be applied in the treatment of those affected by this rare but serious glomerular disease.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"29 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-20DOI: 10.1053/j.ajkd.2025.11.002
Neetika Garg , Carrie Thiessen , Didier A. Mandelbrot
{"title":"Health-Related Quality of Life After Living Kidney Donation: Insights From a Contemporary Meta-Analysis","authors":"Neetika Garg , Carrie Thiessen , Didier A. Mandelbrot","doi":"10.1053/j.ajkd.2025.11.002","DOIUrl":"10.1053/j.ajkd.2025.11.002","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 153-155"},"PeriodicalIF":8.2,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19DOI: 10.1053/j.ajkd.2025.07.023
Jia Wei Teh,Sinead Stoneman,Michelle M O'Shaughnessy
Immunoglobulin A nephropathy (IgAN) is the most common immune-mediated glomerular disease worldwide. Advanced understanding of the role of complement in IgAN pathogenesis has motivated the development of complement inhibition as a therapeutic strategy. Iptacopan, a complement factor B inhibitor, is the first approved complement inhibitor for IgAN. Several other complement inhibitors are being studied in Phase II/III clinical trials. How best to integrate complement inhibition into the evolving treatment paradigm for IgAN remains a challenge. This review provides an overview of the role of complement in the pathogenesis and progression of IgAN and summarizes current and emerging complement-targeted IgAN therapies.
{"title":"Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review.","authors":"Jia Wei Teh,Sinead Stoneman,Michelle M O'Shaughnessy","doi":"10.1053/j.ajkd.2025.07.023","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.07.023","url":null,"abstract":"Immunoglobulin A nephropathy (IgAN) is the most common immune-mediated glomerular disease worldwide. Advanced understanding of the role of complement in IgAN pathogenesis has motivated the development of complement inhibition as a therapeutic strategy. Iptacopan, a complement factor B inhibitor, is the first approved complement inhibitor for IgAN. Several other complement inhibitors are being studied in Phase II/III clinical trials. How best to integrate complement inhibition into the evolving treatment paradigm for IgAN remains a challenge. This review provides an overview of the role of complement in the pathogenesis and progression of IgAN and summarizes current and emerging complement-targeted IgAN therapies.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"22 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19DOI: 10.1053/j.ajkd.2025.11.003
James O. Burton DM, MBChB , Katherine L. Hull MBChB
{"title":"Chronic Pain in Hemodialysis: Beyond the Biochemical Paradigm","authors":"James O. Burton DM, MBChB , Katherine L. Hull MBChB","doi":"10.1053/j.ajkd.2025.11.003","DOIUrl":"10.1053/j.ajkd.2025.11.003","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 156-158"},"PeriodicalIF":8.2,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19DOI: 10.1053/j.ajkd.2025.07.021
Robert Sanchez MPS
{"title":"Why This Research Matters","authors":"Robert Sanchez MPS","doi":"10.1053/j.ajkd.2025.07.021","DOIUrl":"10.1053/j.ajkd.2025.07.021","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages A8-A9"},"PeriodicalIF":8.2,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.1053/j.ajkd.2025.09.006
Telma Pais , José Oliveira da Costa , Mafalda Pinho , Dolores López-Presa , Sofia Jorge , José António Lopes , Joana Gameiro
{"title":"Purpura in a Patient With Nephritic Syndrome: A Quiz","authors":"Telma Pais , José Oliveira da Costa , Mafalda Pinho , Dolores López-Presa , Sofia Jorge , José António Lopes , Joana Gameiro","doi":"10.1053/j.ajkd.2025.09.006","DOIUrl":"10.1053/j.ajkd.2025.09.006","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 1","pages":"Pages A21-A24"},"PeriodicalIF":8.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：